微血栓形成机制与对策新进展-国际临床研究杂志-CSCIED科技核心评价数据库-手机版

微血栓形成机制与对策新进展

Mechanism and countermeasures of microthrombosis

ES评分 0 浏览量：784 下载量：0

DOI	10.12208/j.ijcr.20220354
刊名	国际临床研究杂志 International Journal of Clinical Research
年，卷(期)	2022, 6(8)
作者	罗羽杉,贺娜,赵梓棋,刘凯歌*,
作者单位	西安医学院陕西西安 ;
摘要	微血栓的形成与一系列不同的疾病相关，包括内皮功能损伤、血管活性异常，最终会形成微血栓而造成组织损伤和器官功能障碍。微血栓常出现在小静脉、毛细血管及微循环中，多种疾病均会出现微血栓这类血栓前状态，具体形成机制仍在探索中。研究人体的心脏、肺脏以及肾脏中的一系列微血管疾病之间的关系可能会发现共同的机制，目前认为微血栓的出现可能是血管收缩障碍、免疫效应降低的原因。本综述将探讨出现微血栓患者的各种血液学事件、发病机制、与不良结局相关的生物标志物以及治疗方法。
Abstract	The formation of microthrombus is related to a series of different diseases, including endothelial function damage, abnormal vascular activity, and eventually microthrombus resulting in tissue damage and organ dysfunction. Microthrombosis often occurs in venules, capillaries and microcirculation. Prethrombotic states such as microthrombosis occur in many diseases, and the specific formation mechanism is still being explored. The common mechanism may be found by studying the relationship among a series of microvascular diseases in human heart, lung and kidney. at present, it is believed that the emergence of microthrombus may be the cause of vasoconstriction disorder and decreased immune effect. Thisreview will explore various hematological events, pathogenesis, biomarkers associated with adverse outcomes, and treatments in patients with emerging microthrombosis.
关键词	微血栓；凝血
KeyWord	Microthrombosis; Blood Coagulation Disorder
基金项目
页码	170-174

参考文献
相关文献

[1] 梁英, 马晓春,and 李鑫."p38 MAPK/NF-κB传导通路在脓毒症诱导的内皮细胞损伤和凝血功能障碍中的作用".中国重症医学的创新与发展——第二届中国医师协会重症医学医师分会暨第九届中国病理生理学会危重病医学专业委员会2010年危重病医学全国会议会刊.Ed.. , 2010, 169-170.

[2] Mustafa Y . Evaluation of Tp-e nterval, Tp-e/qt Ratio and Tp-e/ Qtc Ratio in Patients with Acute Pulmonary Thromboembolism[J]. The American Journal of Cardiology, 2018, 121(8):e19-.

[3] Cui XY, Tjønnfjord GE, Kanse SM, Dahm AEA, Iversen N, Myklebust CF, Sun L, Jiang ZX, Ueland T, Campbell JJ, Ho M, Sandset PM. Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia. Sci Rep. 2021 Mar 4;11(1):5127.

[4] Drulovic J, Ivanovic J, Martinovic V, Tamas O, Veselinovic N, Cujic D, Gnjatovic M, Mesaros S, Pekmezovic T. Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies. Mult Scler Relat Disord. 2021 Sep;54:103150.

[5] Velikova G, Banks RE, Gearing A, Hemingway I, Forbes MA, Preston SR, Jones M, Wyatt J, Miller K, Ward U, Al-Maskatti J, Singh SM, Ambrose NS, Primrose JN, Selby PJ. Circulating soluble adhesion molecules E-cadherin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in patients with gastric cancer. Br J Cancer. 1997;76(11):1398-404.

[6] Chiang KC, Rizk JG, Nelson DJ, Krishnamurti L, Subbian S, Imig JD, Khan I, Reddy ST, Gupta A. Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath. Expert Opin Ther Targets. 2022 Jan;26(1):13-28.

[7] Magalhaes GS, Rodrigues-Machado MDG, Motta-Santos D, Campagnole-Santos MJ, Santos RAS. Activation of Ang-(1-7)/Mas Receptor Is a Possible Strategy to Treat Coronavirus (SARS-CoV-2) Infection. Front Physiol. 2020 Jun 19;11:730.

[8] 卢薇,梁英梅,邹平.慢性心力衰竭患者血浆VWF、P-选择素、PAI-1水平变化及其临床意义[J].海南医学,2009,20(03):44-45.

[9] 陈建宇,胡豪飞,刘洋,万启军.狼疮性肾炎患者24 h尿蛋白水平与肾小球微血栓形成的相关性[J].海南医学,2021,32(01):16-21.

[10] 操长春,胡豪飞,周丽,魏径虹,廖德汉,朱日兴,邓志勇,吴维涛,尹盼盼,肖鸿莉,何永成.狼疮性肾炎患者血红蛋白水平与肾小球微血栓形成相关性研究[J].中国中西医结合肾病杂志,2019,20(12):1048-1052.

[11] 徐伟伟. 慢性铁超载加重小鼠腹主动脉粥样硬化病变的研究[D].吉林大学,2016.

[12] 韩栋,卢晓栋.骨质疏松症相关危险因素分析[J].继续医学教育,2019,33(06):73-75.

[13] Patterson KA, Zhang X, Wrobleski SK, Hawley AE, Lawrence DA, Wakefield TW, Myers DD, Diaz JA. Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects. Thromb Res. 2013 Mar;131(3):268-76.

[14] 古丽米热•吐尼牙孜(GuUmire•Tuniyazi). 肥胖与静脉血栓栓塞症相关性的Meta分析[D].新疆医科大学,2015.

[15] Long R, You Y, Li W, Jin N, Huang S, Li T, Liu K, Wang Z. Sodium tanshinone IIA sulfonate ameliorates experimental coronary no-reflow phenomenon through down-regulation of FGL2. Life Sci. 2015 Dec 1;142:8-18.

[16] Shang J F . Construction of Novel Coronavirus Pneumonia Emergency Management System Based on Multi Agent Cooperation Mechanism[J]. Indian Journal of Pharmaceutical Sciences, 2021, 83.

[17] Feuer DS, Handberg EM, Mehrad B, Wei J, Bairey Merz CN, Pepine CJ, Keeley EC. Microvascular Dysfunction as a Systemic Disease: A Review of the Evidence. Am J Med. 2022 Apr 23:S0002-9343(22)00341-2.

[18] Ding Y Z , Wang M , Xia J X , et al. Analysis of the sampling results in both an asymptomatic pregnant female with novel coronavirus pneumonia infection and the neonate[J]. Asian Journal of Surgery, 2021(6).

[19] Hammoud H, Bendari A, Bendari T, Bougmiza I. Histopathological Findings in COVID-19 Cases: A Systematic Review. Cureus. 2022 Jun 1;14(6):e25573. doi: 10.7759/cureus.25573. PMID: 35784976; PMCID: PMC9249248.

[20] Zhang S, Zhang Y, Wang F, Kang D, Wang J, Wang M, Zhang C, Wang Y, Liu H, Zhou B, Wu Y. Incineration experiment of medical waste of novel coronavirus pneumonia (COVID-19) in a mobile animal carcass incinerator. Waste Dispos Sustain Energy. 2021;3(2):177-183.

[21] Martín-Martín J, Martín-Cazorla F, Suárez J, Rubio L, Martín-de-Las-Heras S. Comorbidities and autopsy findings of COVID-19 deaths and their association with time to death: a systematic review and meta-analysis. Curr Med Res Opin. 2022 May;38(5):785-792.

[22] de Laat MA, Pollitt CC, Kyaw-Tanner MT, McGowan CM, Sillence MN. A potential role for lamellar insulin-like growth factor-1 receptor in the pathogenesis of hyperinsulinaemic laminitis. Vet J. 2013 Aug;197(2): 302-6.

[23] Cao B, Jing X, Liu Y, Wen R, Wang C. Comparison of laboratory parameters in mild vs. severe cases and died vs. survived patients with COVID-19: systematic review and meta-analysis. J Thorac Dis. 2022 May;14(5):1478-1487.

[24] Bowles Louise,Platton Sean,Yartey Nada,Dave Minal,Lee Kurtis,Hart Daniel P,MacDonald Vickie,Green Laura,Sivapalaratnam Suthesh,Pasi K John,MacCallum Peter. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19.[J]. The New England journal of medicine,2020,383(3).

[25] Zia A, Russell J, Sarode R, Veeram SR, Josephs S, Malone K, Zhang S, Journeycake J. Markers of coagulation activation, inflammation and fibrinolysis as predictors of poor outcomes after pediatric venous thromboembolism: A systematic review and meta-analysis. Thromb Res. 2017 Dec;160:1-8.

[26] Ricardo J Jose,Ari Manuel. COVID-19 cytokine storm: the interplay between inflammation and coagulation[J]. The Lancet Respiratory Medicine,2020,8(6).

[27] 赵璟,冯丽霞.丹参多酚酸盐在预防脓毒症患者微血栓形成中的应用[J].中西医结合心血管病电子杂志,2016,4(03):103-104.DOI:10.16282/j.cnki.cn11-9336/r.2016.03.049.

[28] 高苗,冯娜,左秀萍,张美霞,张朋勃,徐梦.预防性护理对肺癌患者治疗后深静脉血栓形成率的临床效果:A meta-analysis[J].海南医学院学报,2020,26(08):618-623.

DOI:10.13210/j.cnki.jhmu.20200220.003.

[29] Frere C, Farge D, Schrag D, Prata PH, Connors JM. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol. 2022 May 21;15(1):69.

[30] Eck RJ, Elling T, Sutton AJ, Wetterslev J, Gluud C, van der Horst ICC, Gans ROB, Meijer K, Keus F. Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis. BMJ. 2022 Jul 4;378:e070022.

[31] Woollard KJ, Chin-Dusting J. P-selectin antagonism in inflammatory disease. Curr Pharm Des. 2010;16(37): 4113-8.

引用本文

罗羽杉,贺娜,赵梓棋,刘凯歌*. 微血栓形成机制与对策新进展 [J]. 国际临床研究杂志. 2022; 6; (8). 170 - 174.

文献评论

相关学者

相关机构